Escitalopram

Better treatment for depression is through the looking glass

PaulaJo Malin, Steven Phillip Wengel, Willam J. Burke

Research output: Contribution to journalReview article

3 Citations (Scopus)

Abstract

Depression remains a common and often devastating illness. With the introduction of the selective serotonin reuptake inhibitors in the 1980s, patients were afforded treatment for depression that was both safer and better tolerated than any prior treatment modality offered. Although selective serotonin reuptake inhibitors quickly became the most widely used medications for the treatment of depression, no single agent has been recognized as an obvious first-line choice. Chirality potentially offers one method to improve upon the selective serotonin reuptake inhibitor class. For racemic compounds that differ in stereospecificity, separation into single enantiomers can result in significant changes in potency, tolerability and efficacy. One of the most widely prescribed selective serotonin reuptake inhibitors is citalopram, which exists as a racemic mixture of R- and S-enantiomers. The S-enantiomer escitalopram (Cipralex®, Lundbeck) is the therapeutically active portion of the parent compound and has a proven antidepressant efficacy. The R-enantiomer lacks activity as an antidepressant and has been shown to inhibit the effect of the S-enantiomer when the two are combined. Escitalopram is the most selective member of its class and with minimal effects on the cytochrome P450 system, has a negligible potential for drug-drug interactions. In placebo-controlled trials, escitalopram has consistently demonstrated symptomatic improvement as early as the first to second week of treatment. In addition to antidepressant efficacy, escitalopram also appears to exhibit significant anxiolytic properties. It has also shown efficacy In treating panic disorder and generalized and social anxiety disorders. This is advantageous as many patients who suffer from depression also experience comorbid anxiety disorders.

Original languageEnglish (US)
Pages (from-to)769-779
Number of pages11
JournalExpert Review of Neurotherapeutics
Volume4
Issue number5
DOIs
StatePublished - Sep 1 2004

Fingerprint

Citalopram
Glass
Serotonin Uptake Inhibitors
Depression
Antidepressive Agents
Therapeutics
Panic Disorder
Anti-Anxiety Agents
Anxiety Disorders
Drug Interactions
Cytochrome P-450 Enzyme System
Placebos
Pharmaceutical Preparations

Keywords

  • Antidepressant
  • Binding
  • Efficacy
  • Enantiomer
  • Escitalopram
  • Major depressive disorder
  • Selective serotonin reuptake inhibitor
  • Serotonin tolerability
  • Uptake

ASJC Scopus subject areas

  • Neuroscience(all)
  • Clinical Neurology
  • Pharmacology (medical)

Cite this

Escitalopram : Better treatment for depression is through the looking glass. / Malin, PaulaJo; Wengel, Steven Phillip; Burke, Willam J.

In: Expert Review of Neurotherapeutics, Vol. 4, No. 5, 01.09.2004, p. 769-779.

Research output: Contribution to journalReview article

@article{5975e3b8cd494639946147af32923651,
title = "Escitalopram: Better treatment for depression is through the looking glass",
abstract = "Depression remains a common and often devastating illness. With the introduction of the selective serotonin reuptake inhibitors in the 1980s, patients were afforded treatment for depression that was both safer and better tolerated than any prior treatment modality offered. Although selective serotonin reuptake inhibitors quickly became the most widely used medications for the treatment of depression, no single agent has been recognized as an obvious first-line choice. Chirality potentially offers one method to improve upon the selective serotonin reuptake inhibitor class. For racemic compounds that differ in stereospecificity, separation into single enantiomers can result in significant changes in potency, tolerability and efficacy. One of the most widely prescribed selective serotonin reuptake inhibitors is citalopram, which exists as a racemic mixture of R- and S-enantiomers. The S-enantiomer escitalopram (Cipralex{\circledR}, Lundbeck) is the therapeutically active portion of the parent compound and has a proven antidepressant efficacy. The R-enantiomer lacks activity as an antidepressant and has been shown to inhibit the effect of the S-enantiomer when the two are combined. Escitalopram is the most selective member of its class and with minimal effects on the cytochrome P450 system, has a negligible potential for drug-drug interactions. In placebo-controlled trials, escitalopram has consistently demonstrated symptomatic improvement as early as the first to second week of treatment. In addition to antidepressant efficacy, escitalopram also appears to exhibit significant anxiolytic properties. It has also shown efficacy In treating panic disorder and generalized and social anxiety disorders. This is advantageous as many patients who suffer from depression also experience comorbid anxiety disorders.",
keywords = "Antidepressant, Binding, Efficacy, Enantiomer, Escitalopram, Major depressive disorder, Selective serotonin reuptake inhibitor, Serotonin tolerability, Uptake",
author = "PaulaJo Malin and Wengel, {Steven Phillip} and Burke, {Willam J.}",
year = "2004",
month = "9",
day = "1",
doi = "10.1586/14737175.4.5.769",
language = "English (US)",
volume = "4",
pages = "769--779",
journal = "Expert Review of Neurotherapeutics",
issn = "1473-7175",
publisher = "Expert Reviews Ltd.",
number = "5",

}

TY - JOUR

T1 - Escitalopram

T2 - Better treatment for depression is through the looking glass

AU - Malin, PaulaJo

AU - Wengel, Steven Phillip

AU - Burke, Willam J.

PY - 2004/9/1

Y1 - 2004/9/1

N2 - Depression remains a common and often devastating illness. With the introduction of the selective serotonin reuptake inhibitors in the 1980s, patients were afforded treatment for depression that was both safer and better tolerated than any prior treatment modality offered. Although selective serotonin reuptake inhibitors quickly became the most widely used medications for the treatment of depression, no single agent has been recognized as an obvious first-line choice. Chirality potentially offers one method to improve upon the selective serotonin reuptake inhibitor class. For racemic compounds that differ in stereospecificity, separation into single enantiomers can result in significant changes in potency, tolerability and efficacy. One of the most widely prescribed selective serotonin reuptake inhibitors is citalopram, which exists as a racemic mixture of R- and S-enantiomers. The S-enantiomer escitalopram (Cipralex®, Lundbeck) is the therapeutically active portion of the parent compound and has a proven antidepressant efficacy. The R-enantiomer lacks activity as an antidepressant and has been shown to inhibit the effect of the S-enantiomer when the two are combined. Escitalopram is the most selective member of its class and with minimal effects on the cytochrome P450 system, has a negligible potential for drug-drug interactions. In placebo-controlled trials, escitalopram has consistently demonstrated symptomatic improvement as early as the first to second week of treatment. In addition to antidepressant efficacy, escitalopram also appears to exhibit significant anxiolytic properties. It has also shown efficacy In treating panic disorder and generalized and social anxiety disorders. This is advantageous as many patients who suffer from depression also experience comorbid anxiety disorders.

AB - Depression remains a common and often devastating illness. With the introduction of the selective serotonin reuptake inhibitors in the 1980s, patients were afforded treatment for depression that was both safer and better tolerated than any prior treatment modality offered. Although selective serotonin reuptake inhibitors quickly became the most widely used medications for the treatment of depression, no single agent has been recognized as an obvious first-line choice. Chirality potentially offers one method to improve upon the selective serotonin reuptake inhibitor class. For racemic compounds that differ in stereospecificity, separation into single enantiomers can result in significant changes in potency, tolerability and efficacy. One of the most widely prescribed selective serotonin reuptake inhibitors is citalopram, which exists as a racemic mixture of R- and S-enantiomers. The S-enantiomer escitalopram (Cipralex®, Lundbeck) is the therapeutically active portion of the parent compound and has a proven antidepressant efficacy. The R-enantiomer lacks activity as an antidepressant and has been shown to inhibit the effect of the S-enantiomer when the two are combined. Escitalopram is the most selective member of its class and with minimal effects on the cytochrome P450 system, has a negligible potential for drug-drug interactions. In placebo-controlled trials, escitalopram has consistently demonstrated symptomatic improvement as early as the first to second week of treatment. In addition to antidepressant efficacy, escitalopram also appears to exhibit significant anxiolytic properties. It has also shown efficacy In treating panic disorder and generalized and social anxiety disorders. This is advantageous as many patients who suffer from depression also experience comorbid anxiety disorders.

KW - Antidepressant

KW - Binding

KW - Efficacy

KW - Enantiomer

KW - Escitalopram

KW - Major depressive disorder

KW - Selective serotonin reuptake inhibitor

KW - Serotonin tolerability

KW - Uptake

UR - http://www.scopus.com/inward/record.url?scp=4444346665&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4444346665&partnerID=8YFLogxK

U2 - 10.1586/14737175.4.5.769

DO - 10.1586/14737175.4.5.769

M3 - Review article

VL - 4

SP - 769

EP - 779

JO - Expert Review of Neurotherapeutics

JF - Expert Review of Neurotherapeutics

SN - 1473-7175

IS - 5

ER -